Anemia and Left Ventricular Function in End-Stage Renal Disease

  • Allan D. Sniderman
  • Jonathan Silberberg
  • Sarah Prichard
  • Paul E. Barré
Part of the Topics in Renal Medicine book series (TIRM, volume 10)


The circulatory system developed in order to deliver essential nutrients to cells and to remove waste materials as required. It is actually two systems in series: 1) the pulmonary circulation, and 2) the systemic circulation. Anemia, by diminishing the oxygen content per volume of blood, requires an increase in the total volume of blood per unit time reaching key tissues such as the heart, so that energy requirements may be met. In this chapter, we briefly review the impact of anemia on the right and left ventricles in patients with end-stage renal disease (ESRD). In summary, we believe that the available evidence establishes that anemia is a real but limited cause of left ventricular hypertrophy in such patients, and its correction produces real but limited reduction of left ventricular hypertrophy. However, whether correction of anemia and regression of left ventricular hypertrophy will result in a significant reduction in mortality remains to be determined.


Left Ventricular Hypertrophy Diastolic Dysfunction Ventricular Hypertrophy Continuous Ambulatory Peritoneal Dialysis Recombinant Human Erythropoietin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grossman W, Jones D, McLaurin LP. 1975. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56–64.PubMedCrossRefGoogle Scholar
  2. 2.
    Olivetti C, Lagrasta G, Quaini F, Ricci R, Moccia G, Capasso JM, Anversa P. 1989. Capillary growth in anemia-induced ventricular wall remodeling in the rat heart. Circ Res 65(5):1182–1192.PubMedCrossRefGoogle Scholar
  3. 3.
    Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E. 1988. Myocardial interstitial fibrosis in experimental uremia— implications for cardiac compliance. Kidney Int 33:804–811.PubMedCrossRefGoogle Scholar
  4. 4.
    Varat MA, Adolph RJ, Fowler NO. 1972. Fundamentals of clinical cardiology: Cardiovascular effects of anemia. Am Heart J 83(3):415–426.CrossRefGoogle Scholar
  5. 5.
    Sniderman A, Burdon T, Homan J, Salerno TA. 1984. Pulmonary blood flow. J Thorac Cardiovasc Surg 87(l):130–135.Google Scholar
  6. 6.
    Silberberg JS, Rahal DR, Patton DR, Sniderman AD.1989. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal failure. Am J Cardiol 64(3):222–224.CrossRefGoogle Scholar
  7. 7.
    Bernardi D, Bernini L, Cini G, Brandinelli Geri A, Urti DA, Bonechi I. 1985. Asymmetric septal hypertrophy in uremicnormotensive patients on regular hemodialysis: An M-mode and two-dimensional echocardiographic study. Nephron 39:30–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Hüting J, Kramer W, Schütterle G, Wisemann V. 1988. Analysis of left-ventricular changes associated with chronic hemodialysis. A noninvasive follow-up study. Nephron 49: 284–290.Google Scholar
  9. 9.
    Parfrey PS, Harriett JD, Griffiths SM, Taylor R, Hand J, King A, Barr© PE. 1990. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 55:114–120.PubMedCrossRefGoogle Scholar
  10. 10.
    Casale P, Devereux R, Milner M, Zullo G, Harshfield G, Pickering T, Laragh J. 1986. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105:173–178.PubMedGoogle Scholar
  11. 11.
    Frohlich E. 1986. Left ventricular hypertrophy as a risk factor. Cardiol Clin 4:137–145.PubMedGoogle Scholar
  12. 12.
    Kannel WB, Abbott R. 1986. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognised myocardial infarction: The Framingham Study. Am Heart J 111:391–397.PubMedCrossRefGoogle Scholar
  13. 13.
    Levy D, Garrison RJ, Savagh DD, Kannel WB, Castelli WP. Left ventricular mass predicts coronary disease events independent of the standard risk factors. Circulation 76(4):435.Google Scholar
  14. 14.
    Silberberg JS, Barré PE, Prichard SS, Sniderman AD. 1989. Impact on left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286–290.PubMedCrossRefGoogle Scholar
  15. 15.
    Winearls CG, Oliver DO, Pippard MJ, Reic C, Downing MR, Cotes PM. 1986. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic hemodialysis. Lancet 2:1175–1177.PubMedCrossRefGoogle Scholar
  16. 16.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. 1987. Correction of anemia of end-stage renal disease with recombinant human erythropoietin: Result of a phase I and II clinical trial. N EnglJ Med 316:73–78.CrossRefGoogle Scholar
  17. 17.
    Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. 1987. Benefits and risks of protected treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 295:1017–1020.CrossRefGoogle Scholar
  18. 18.
    Bommer J, Alexiou C, Müller-Bühl U, Eifert TJ, Ritz E. 1987. Recombinant human erythropoietin therapy in haemodialysis patients— Dose determination and clinical experience. Nephrol Dial Transplant 2:238–242.PubMedGoogle Scholar
  19. 19.
    Low I, Grutzmacher P, Bergmann M, Schoeppe W. 1989. Echocardiographic findings in patients on maintenance haemodialysis substituted with recombinant erythropoietin. Clin Nephrol 31:26–30.PubMedGoogle Scholar
  20. 20.
    Raine AEG. 1988. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1:97–100.PubMedCrossRefGoogle Scholar
  21. 21.
    London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB. 1989. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36:878–882.PubMedCrossRefGoogle Scholar
  22. 22.
    Silberberg JS, Racine N, Barré PE, Snideman AD. 1989. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant erythropoietin. Can J Cardiol 6(1):1–4.Google Scholar
  23. 23.
    Rosenlöf K, Grönhagen-Riska C, Sovijärvi A, Honkanen E, Tikkanen I, Ekstrand A, Piirilä P, Fyhrquist F. 1989. Beneficial effects of erythropoietin on haematological parameters, aerobic capacity, and body fluid composition in patients on haemodialysis. J Intern Med 226:311–317.PubMedCrossRefGoogle Scholar
  24. 24.
    Verbeelen D, Bossuyt A, Smitz J, Herman A, Dratwa M, Jonckheer MH. 1989. Hemo-dynamics of patients with renal failure treated with recombinant human erythropoietin. Clin Nephrol 31(1):6–11.PubMedGoogle Scholar
  25. 25.
    Nonnast-Daniel B, Schäffer, Frei U.1989. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin. In Baldamus CA, Scigalla P, Wieczorek L, Koch KM(eds), Hemodynamic and Rheologic Changes, vol. 76. Basel: Karger, pp. 283–291.Google Scholar
  26. 26.
    Grützmacher P, Scheuermann E, Löw I, Bergmann M, Rauber K, Baum R, Heuser J, Schoeppe W. 1988. Correction of renal anaemia by recombinant human erythropoietin: Effects on myocardial function. Contrib Nephrol. 66:176–184.PubMedGoogle Scholar
  27. 27.
    Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KAA, Coles GA, Williams JD. 1990. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335:489–493.PubMedCrossRefGoogle Scholar
  28. 28.
    Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J. 1989. Recombinant human erythropoietin treatment in predialysis patients: A double-blind placebo-controlled trial. Ann Intern Med 110:108–114.PubMedGoogle Scholar
  29. 29.
    London GM, de Vernejoul MC, Fabiani F, Marchais S, Guerin A, Metivier F, Chappuis P, Llach F. 1989. Association between aluminum accumulation and cardiac hypertrophy in hemodialyzed patients. Am J. Kidney Dis. 13:75–83.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Allan D. Sniderman
  • Jonathan Silberberg
  • Sarah Prichard
  • Paul E. Barré

There are no affiliations available

Personalised recommendations